auristatin f

Auristatin F is an effective inhibitor of microtubule and vascular damaging agent. Auristatin F can be used in antibody-drug conjugates.

MMAF-OMe (Monomethyl auristatin F methyl ester) is an antitubulin agent which inhibits several tumor cell lines with IC50s of 0.056 nM, 0.166 nM, 0.183 nM, and 0.449 nM for MDAMB435/5T4, MDAMB361DYT2, MDAMB468, and Raji (5T4-) cell lines, respectively. MMAF-Ome is also an ADC cytotoxin.

McMMAF is a protective group-conjugated MMAF. MMAF is a potent tubulin polymerization inhibitor.It is a MMAF derivative having a Maleimidocaproyl linker (MC linker), which is ready to conjugate to antibody or other proteins or biopolymers. Mafodotin is a useful agent for make antibody drug conjugate (ADC) for targeted drug delivery.

MMAF Hydrochloride is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A. MMAF Hydrochloride is an effective tubulin polymerization inhibitor and is used as an antitumor compound.

MMAF sodium is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A. MMAF sodium is an effective tubulin polymerization inhibitor and is used as an antitumor agent.

MMAF (MonoMethyl auristatin F), an antimitotic agent, inhibits cell division by blocking the polymerization of tubulin.

D8-MMAF is a microtubule destroyer, deuterated form of MMAF.

MAL-di-EG-Val-Cit-PAB-MMAF is a chemical compound consisting of the linker (MAL-di-EG-Val-Cit-PAB) and the potent tubulin polymerization inhibitor (MMAF, Monomethyl auristatin F) [1].

MC-Val-Cit-PAB-MMAF is an antibody-drug conjugate (ADC) component that exhibits antitumor properties through the action of the tubulin inhibitor, monomethyl auristatin F (MMAF), which is connected by a cathepsin-cleavable linker, MC-Val-Cit-PAB.

MAL-PEG4-MMAF is a maleimido functionalized derivative of MMAF (Monomethyl auristatin F) with PEG4 linker. The maleimido functional group can be easily conjugated to protein carriers (such as antibody or enzyme). MAL-PEG4-MMAF is a useful precursor for ma

Mal-PEG8-Val-Cit-PAB-MMAF, a drug-linker conjugate utilized for antibody-drug conjugates (ADCs), includes a cleavable linker system and the potent tubulin inhibitor monomethyl auristatin F (MMAF), designed for targeted cancer therapy.

Val-Cit-PAB-MMAF sodium is an agent-linker conjugate used in antibody-drug conjugates (ADCs), comprising the peptide linker Val-Cit-PAB and the cytotoxic agent monomethyl auristatin F (MMAF), which inhibits tubulin polymerization [1].

Vorsetuzumab mafodotin, a humanized anti-CD70 monoclonal antibody, conjugates with monomethyl auristatin F (MMAF) through Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology. This affinity allows targeting of various solid tumors and cancers such as renal cell carcinoma, pancreatic, ovarian, and lung cancers, alongside multiple myeloma and several forms of non-Hodgkin lymphoma, all of which express CD70.

AGS-16C3F is an antibody-drug conjugate (ADC) targeting ENPP3 (also known as CD203c). This product consists of a humanized IgG1 monoclonal antibody against ENPP3 conjugated to the microtubule inhibitor monomethyl auristatin F (MMAF) via a non-cleavable linker. AGS-16C3F functions by specifically binding to ENPP3 on the surface of tumor cells, undergoing internalization, and releasing MMAF intracellularly to induce cell cycle arrest and apoptosis. It exhibits potent anti-tumor and anti-proliferative activity in ENPP3-expressing metastatic renal cell carcinoma (mRCC) and systemic mastocytosis.